- A retrospective study of patients with esophageal cancer and positive lymph nodes (LNs) after neoadjuvant treatment showed better OS associated with adjuvant therapy.
Why this matters
- Positive LNs after neoadjuvant therapy is an indicator of worse diagnosis, but 2 small studies and a National Cancer Database study examining the effect of adjuvant therapy have returned mixed results.
- The study uses a larger and more detailed database in an effort to study whether adjuvant therapy improves survival in this population.
- Multicenter, retrospective cohort study (n=1082).
- Funding: None disclosed.
- 19.3% of patients had adjuvant therapy. Of those who received adjuvant therapy, 79.9% had adjuvant chemotherapy alone, 14.4% had chemoradiation, and 5.7% had radiation alone.
- Adjuvant therapy was associated with a longer median postresection Kaplan-Meier survival (2.6 vs 2.3 years). The survival benefit was greatest in the early part of the curves (Wilcoxon P=.02; log-rank P=.06).
- Cox proportional hazards modeling found an association between adjuvant treatment and mortality (HR, 0.76; P=.005) after adjustment for a range of demographic and clinical factors.
- Retrospective analysis.